A number of research firms have changed their ratings and price targets for BioTime (NYSEMKT: BTX):

  • 10/10/2017 – BioTime was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “BioTime, Inc. is a clinical-stage biotechnology company focused on developing and commercializing novel therapies in the field of regenerative medicine. The foundation of its core therapeutic technology platform is pluripotent cells that are capable of becoming any of the cell types in the human body. BioTime’s research and other activities have resulted, over time, in the creation of other subsidiaries that address other non-therapeutic market opportunities such as cancer diagnostics, drug development and cell research products, and mobile health software applications. “
  • 10/6/2017 – BioTime was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating.
  • 10/3/2017 – BioTime was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “BioTime, Inc. is a clinical-stage biotechnology company focused on developing and commercializing novel therapies in the field of regenerative medicine. The foundation of its core therapeutic technology platform is pluripotent cells that are capable of becoming any of the cell types in the human body. BioTime’s research and other activities have resulted, over time, in the creation of other subsidiaries that address other non-therapeutic market opportunities such as cancer diagnostics, drug development and cell research products, and mobile health software applications. “
  • 9/28/2017 – BioTime was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating.
  • 8/25/2017 – BioTime was upgraded by analysts at BidaskClub from a “strong sell” rating to a “sell” rating.
  • 8/14/2017 – BioTime was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “BioTime, Inc. is a clinical-stage biotechnology company focused on developing and commercializing novel therapies in the field of regenerative medicine. The foundation of its core therapeutic technology platform is pluripotent cells that are capable of becoming any of the cell types in the human body. BioTime’s research and other activities have resulted, over time, in the creation of other subsidiaries that address other non-therapeutic market opportunities such as cancer diagnostics, drug development and cell research products, and mobile health software applications. “

Shares of BioTime, Inc. (NYSEMKT BTX) traded down 1.44% during mid-day trading on Thursday, reaching $2.73. 295,289 shares of the company’s stock were exchanged. BioTime, Inc. has a 1-year low of $2.47 and a 1-year high of $3.96. The company’s 50 day moving average is $2.82 and its 200 day moving average is $3.01. The stock has a market capitalization of $316.14 million, a PE ratio of 4.59 and a beta of 1.37.

In other BioTime news, Director Broadwood Partners, L.P. bought 10,000 shares of BioTime stock in a transaction dated Tuesday, August 22nd. The stock was acquired at an average cost of $2.60 per share, for a total transaction of $26,000.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Over the last ninety days, insiders have acquired 173,896 shares of company stock worth $481,220.

BioTime, Inc is a clinical-stage biotechnology company focused on developing and commercializing products addressing degenerative diseases. Its clinical programs are based on two platform technologies: pluripotent stem cells and cell/drug delivery platform technologies. The foundation of its cell delivery platform is its HyStem cell and drug delivery matrix technology.

Receive News & Ratings for BioTime Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioTime Inc and related companies with MarketBeat.com's FREE daily email newsletter.